In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Cosmetics Health

Teva will invest in OTC as ‘core asset’ for group

This article is powered by OTC Bulletin & The Rose Sheet

  • News

Executive Summary

Teva’s OTC portfolio remains a “core asset” in which the Israeli generics giant will continue to invest, according to chief executive officer Kåre Schultz.

You may also be interested in...



Teva Divests US OTC Store Brand Portfolio to PL Developments

Israel's Teva has trimmed its OTC portfolio by offloading its US store brands to PL Developments.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Table

View full table

Topics

Tags:
Business Strategies Cosmetics Health
Latest Headlines

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

China VBP, Localization And Other Strategies - How Far And Which Way?

See All
UsernamePublicRestriction

Register

RS122358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By